Literature DB >> 26115159

Ankaferd blood stopper decreases postoperative bleeding and number of transfusions in patients treated with clopidogrel: a double-blind, placebo-controlled, randomized clinical trial.

Mehmet Besir Akpinar1, Atakan Atalay, Hakan Atalay, Omer Faruk Dogan.   

Abstract

BACKGROUND: The risk of reoperation due to bleeding after open heart surgery is 2.2%-4.2%. Patients who undergo reoperation have a two to six times greater mortality rate. Risk factors for reoperation include: older age, low body mass index, time on extracorporeal circulation, and emergency operations. In coronary artery bypass graft (CABG) patients who are treated preoperatively with antiplatelets, including clopidogrel, the source of postoperative bleeding may be difficult to detect. The aim of this study was to investigate the effectiveness of local Ankaferd blood stopper (ABS) to prevent mediastinal bleeding in CABG patients who were treated with clopidogrel and acetylsalicylic acid (ASA) preoperatively.
METHODS: Twenty-five emergency CABG patients premedicated with clopidogrel and ASA as antiplatelet drugs were included in the study (Group 1). An additional twenty-five patients who were premedicated with the same antiplatelet agents were selected as a control group (Group 2). Preoperative clinical characteristics of the two groups were comparable. At the end of the surgery, 4-10 mL of ABS solution was sprayed on the mediastinal and epicardial tissue following protamine administration in Group1. We compared postoperative total mediastinal bleeding, reoperation rate and total blood and blood products transfused between the two groups.
RESULTS: There was no mortality in either of the two groups. Mean postoperative bleeding was 430 mL in the ABS group, and 690 mL in the CG group (P = .044). In the ICU, bleeding in groups 1 and 2 was 610 mL and 980 mL, respectively (P = .025); total bleeding from the mediastinum was 830 mL and 1490 mL, respectively (P = .001) and the amount of autotransfusion was 210 mL and 400 mL (P = .003). Total transfusion of PRBCs in the operating room in groups 1 and 2 was 0.3 and 0.8, respectively (P = .003). No patients in the ABS group needed surgical revision due to severe bleeding or cardiac tamponade.
CONCLUSION: The use of local ABS reduces bleeding, transfusion requirements of packed red blood cells, platelets and total blood units in patients premedicated with clopidogrel and ASA undergoing emergent CABG .

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26115159     DOI: 10.1532/hsf.1256

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  4 in total

1.  Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level.

Authors:  Emre Huri; Engin Dogantekin; Murvet Hayran; Umit Yavuz Malkan; Mine Ergun; Aysegul Firat; Yavuz Beyazit; Huseyin Ustun; Murat Kekilli; Mumtaz Dadali; Muzeyyen Astarci; Ibrahim C Haznedaroglu
Journal:  Springerplus       Date:  2016-11-08

Review 2.  Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Authors:  Cem Simsek; Sebnem Selek; Meltem Koca; Ibrahim Celal Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-07-27

3.  Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines.

Authors:  Seyhan Turk; Umit Yavuz Malkan; Mehdi Ghasemi; Helin Hocaoglu; Duygu Mutlu; Gursel Gunes; Salih Aksu; Ibrahim Celalettin Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-02-10

Review 4.  Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper).

Authors:  Rafiye Ciftciler; Ali Erdinc Ciftciler; Umit Yavuz Malkan; Ibrahim C Haznedaroglu
Journal:  SAGE Open Med       Date:  2020-02-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.